Oral mTOR Inhibitor Everolimus in Patients With Gemcitabine-Refractory Metastatic Pancreatic Cancer
- 10 January 2009
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 27 (2), 193-198
- https://doi.org/10.1200/jco.2008.18.9514
Abstract
Purpose The PI3K/Akt/mTOR pathway is activated in the majority of pancreatic cancers, and inhibition of this pathway has antitumor effects in preclinical studies. We performed a multi-institutional...This publication has 48 references indexed in Scilit:
- Dose- and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus: A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid TumorsJournal of Clinical Oncology, 2008
- Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With Advanced Solid TumorsJournal of Clinical Oncology, 2008
- Cancer Statistics, 2008CA: A Cancer Journal for Clinicians, 2008
- Stress and mTORture signalingOncogene, 2006
- Upstream of the mammalian target of rapamycin: do all roads pass through mTOR?Oncogene, 2006
- mTOR and cancer: insights into a complex relationshipNature Reviews Cancer, 2006
- Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II studyInvestigational New Drugs, 2005
- The rapamycin analog CCI-779 is a potent inhibitor of pancreatic cancer cell proliferationBiochemical and Biophysical Research Communications, 2005
- Insulin-like growth factors and neoplasiaNature Reviews Cancer, 2004
- Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genesCell, 1988